346 related articles for article (PubMed ID: 28545225)
21. Pharmacogenomics in the Americas: the impact of genetic admixture.
Suarez-Kurtz G; Pena SD
Curr Drug Targets; 2006 Dec; 7(12):1649-58. PubMed ID: 17168840
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogeomic implications of population diversity in Latin America: TPMT and NUDT15 polymorphisms and thiopurine dosing.
Suarez-Kurtz G; Araújo GS; de Sousa SJ
Pharmacogenet Genomics; 2020 Jan; 30(1):1-4. PubMed ID: 31651720
[TBL] [Abstract][Full Text] [Related]
23. Genetic polymorphisms of pharmacogenomic VIP variants in the Yi population from China.
Yan M; Li D; Zhao G; Li J; Niu F; Li B; Chen P; Jin T
Gene; 2018 Mar; 648():54-62. PubMed ID: 29337087
[TBL] [Abstract][Full Text] [Related]
24. FUT2 polymorphism in Latin American populations.
Soejima M; Koda Y
Clin Chim Acta; 2020 Jun; 505():1-5. PubMed ID: 32070726
[TBL] [Abstract][Full Text] [Related]
25. Interethnic comparisons of important pharmacology genes using SNP databases: potential application to drug regulatory assessments.
Chen J; Teo YY; Toh DS; Sung C
Pharmacogenomics; 2010 Aug; 11(8):1077-94. PubMed ID: 20712526
[TBL] [Abstract][Full Text] [Related]
26. Advances and challenges in hereditary cancer pharmacogenetics.
Cascorbi I; Werk AN
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):73-82. PubMed ID: 27603572
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman RA
Biotechniques; 2005 Oct; 39(4):565-8. PubMed ID: 16235569
[TBL] [Abstract][Full Text] [Related]
28. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
O'Donnell PH; Ratain MJ
Mol Oncol; 2012 Apr; 6(2):251-9. PubMed ID: 22321460
[TBL] [Abstract][Full Text] [Related]
29. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
Wellmann R; Borden BA; Danahey K; Nanda R; Polite BN; Stadler WM; Ratain MJ; O'Donnell PH
Cancer; 2018 Jul; 124(14):3052-3065. PubMed ID: 29742281
[TBL] [Abstract][Full Text] [Related]
30. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.
Huang RS; Dolan ME
Pharmacogenomics; 2010 Apr; 11(4):471-4. PubMed ID: 20350124
[TBL] [Abstract][Full Text] [Related]
31. Somatic pharmacogenomics in cancer.
Ikediobi ON
Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
[TBL] [Abstract][Full Text] [Related]
32. Modern developments in germline pharmacogenomics for oncology prescribing.
Reizine NM; O'Donnell PH
CA Cancer J Clin; 2022 Jul; 72(4):315-332. PubMed ID: 35302652
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription.
Maillard M; Louveau B; Vilquin P; Goldwirt L; Thomas F; Mourah S
Therapie; 2022; 77(2):171-183. PubMed ID: 34922740
[TBL] [Abstract][Full Text] [Related]
34. Admixture and genetic relationships of Mexican Mestizos regarding Latin American and Caribbean populations based on 13 CODIS-STRs.
Salazar-Flores J; Zuñiga-Chiquette F; Rubi-Castellanos R; Álvarez-Miranda JL; Zetina-Hérnandez A; Martínez-Sevilla VM; González-Andrade F; Corach D; Vullo C; Álvarez JC; Lorente JA; Sánchez-Diz P; Herrera RJ; Cerda-Flores RM; Muñoz-Valle JF; Rangel-Villalobos H
Homo; 2015 Feb; 66(1):44-59. PubMed ID: 25435058
[TBL] [Abstract][Full Text] [Related]
35. New perspectives in personalised medicine for ethnicity in cancer: population pharmacogenomics and pharmacometrics.
Nair S; LLerena A
Drug Metab Pers Ther; 2018 Jun; 33(2):61-64. PubMed ID: 29688886
[No Abstract] [Full Text] [Related]
36. Pharmacogenomics: from bedside to clinical practice.
Marsh S; McLeod HL
Hum Mol Genet; 2006 Apr; 15 Spec No 1():R89-93. PubMed ID: 16651374
[TBL] [Abstract][Full Text] [Related]
37. The role and impact of SNPs in pharmacogenomics and personalized medicine.
Laing RE; Hess P; Shen Y; Wang J; Hu SX
Curr Drug Metab; 2011 Jun; 12(5):460-86. PubMed ID: 21453271
[TBL] [Abstract][Full Text] [Related]
38. Genetic databases in pharmacogenomics: the Frequency of Inherited Disorders Database (FINDbase).
Georgitsi M; Patrinos GP
Methods Mol Biol; 2013; 1015():321-36. PubMed ID: 23824866
[TBL] [Abstract][Full Text] [Related]
39. Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences-Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting.
Peñas-LLedó E; Terán E; Sosa-Macías M; Galaviz-Hernández C; Gil JP; Nair S; Diwakar S; Hernández I; Lara-Riegos J; Ramírez-Roa R; Verde I; Tarazona-Santos E; Molina-Guarneros J; Moya G; Rägo L; LLerena A
Clin Ther; 2020 Aug; 42(8):1595-1610.e5. PubMed ID: 32782137
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics: Driving Personalized Medicine.
Sadee W; Wang D; Hartmann K; Toland AE
Pharmacol Rev; 2023 Jul; 75(4):789-814. PubMed ID: 36927888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
